You are here

Article Text

Article menu

Download PDFPDF

XML
PostScript
Letter
Potential utility of the Genedrive point-of-care test for HCV RNA detection
  1. Alba Llibre1,2,
  2. Yusuke Shimakawa3,
  3. Darragh Duffy1,2
  1. 1 Immunobiology of Dendritic Cells, Institut Pasteur, Paris, France
  2. 2 Inserm U1223, Institut Pasteur, Paris, France
  3. 3 Unité d’Epidémiolotie des Maladies Emergentes, Institut Pasteur, Paris, France
  1. Correspondence to Darragh Duffy, Immunobiologie des cellules dendritiques, Institut Pasteur, Paris 75015, France; darragh.duffy{at}pasteur.fr

https://doi.org/10.1136/gutjnl-2018-317218

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    In an article in Gut,1 Lemoine and Tillman reviewed our recent publication on the development and validation of a novel point-of-care (POC) HCV viral assay.2 They acknowledge that Genedrive is the only CE-In Vitro Diagnostic-qualified device for HCV detection, and that the limit of detection (LOD: 1406–3203 IU/mL) permits identification of the vast majority of HCV chronic cases.3 However, they emphasise some limitations of the study and Genedrive. One limitation highlighted is the need for plasma which is still required for 100% of HCV clinical tests. Nevertheless, recent studies demonstrated microfluidic plasma separation without centrifugation4 or with low-cost hand-powered paper centrifuges.5 It is feasible to foresee such devices overcoming the need for conventional centrifuges and facilitating Genedrive testing.

    They also question whether 15 µL of plasma can be obtained by fingerprick. Published studies report 20–25 µL …

    View Full Text